BioWorld

Aug. 1, 2008

BMS After ImClone; Offers $60 per Share for Erbitux Partner

On the heels of Roche Holdings AG's $44 billion offer for Genentech Inc., as potentially the biggest buyout bid in the industry, another big pharma has made a play for its biotech collaborator. (BioWorld Today) Read More

No New Trials Needed for Cadence's Acetavance

iPS Cells from ALS Patients May Help Research, Therapy

FDA Restrictions on ESAs Bring Wall Street Yawns

Genmab, GSK CLL Drug Sails Through Pivotal Test

NewCo News: Sierra Raises $21.5M to Boost its CNS Drug Delivery Mode

AtheroGenics Riding High in Positive Diabetes Trial

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Feb. 3, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...